The study showed that the beneficial effect of the IL-1β inhibitor canakinumab in patients with a baseline high-sensitivity C-reactive protein of ≥2 mg/L and history of MI did not differ between participants with and without T2DM (11, 29). Here, IL1B is linked to type 2 diabetes mellitus.